Safety and efficacy of Osimertinib in Lung cancer patients with newly developed T790m Mutation previously treated with EGFR-TKIs

Trial Profile

Safety and efficacy of Osimertinib in Lung cancer patients with newly developed T790m Mutation previously treated with EGFR-TKIs

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Nov 2017 New trial record
    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top